

November 8, 2021

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Cadilahc

Re.: Press Release


Dear Sir / Madam,

Please find enclosed a copy of press release dated November 8, 2021 titled "**Cadila Healthcare Ltd., to supply 1 crore doses of ZyCoV-D, the world's first Plasmid DNA vaccine to the Government of India**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,
For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Cadila Healthcare Ltd., to supply 1 crore doses of ZyCoV-D, the world's first Plasmid DNA vaccine to the Government of India

Ahmedabad, November 8, 2021

Zydus Cadila has received an order to supply one crore doses of ZyCoV-D, the world's first Plasmid DNA Vaccine, to the Government of India at Rs. 265 per dose and the needle-free applicator being offered at Rs. 93 per dose, excluding GST. The pricing has been decided in consultation with the Government of India.

Speaking on the development, Managing Director of the company, Dr. Sharvil Patel said, "We are happy to support the Government's vaccination programme with ZyCoV-D. The needle-free application of the vaccination, we hope, will motivate many more to vaccinate and safeguard themselves from COVID-19, especially children and young adults in the age group of 12 to 18 years."

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus. It is also the first COVID-19 vaccine which is needle-free and administered using The PharmaJet® a needle free applicator to ensure painless intradermal vaccine delivery which also leads to a significant reduction in any kind of major side effects.

ZyCoV-D has shown good stability at temperatures of around 25 degrees for atleast three months. The thermostability of the vaccine will help in easy transportation and storage of the vaccine without any problems of fluctuations in temperature. For prolonged use, a temperature of 2-8 degrees is sufficient. Also being a DNA plasmid vaccine, ZyCoV-D doesn't have any problem associated with vector based immunity. The DNA Plasmid platform allows generating new construct quickly to deal with mutations in the virus.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.